Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...
Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development
Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million...
Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine
China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...
China Resources Double-Crane Gains Approval for Definity in China
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the...
XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life...
Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
AnchorDx’s UriFind Receives Breakthrough Therapy Designation for Urothelial Carcinoma
China-based Guangzhou AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has obtained a...
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...
Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...
CSPC Pharmaceutical Reports Q3 2022 Financials with 13.8% Revenue Growth
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its Q3 2022 financial results, reporting...
Tianjin Tianyao Fined for Anti-Monopoly Violations in Carmustine Sales
China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD...
China Releases Third Batch of VAT Discounts for Anti-Tumor and Rare Disease Drugs
The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...
OrbusNeich Files for IPO on Hong Kong Stock Exchange
Vascular intervention specialist OrbusNeich Medical Group Limited, a Wholly Owned Foreign Enterprise (WOFE) based in...
Immorna’s JCXH-221 mRNA Vaccine Cleared by FDA for Phase I/II Study
Immorna (Hangzhou) Biotechnology Co., Ltd has announced that the US FDA has cleared its investigational...
Henlius Biotech Partners with Shantou Central Hospital for Clinical Study Collaboration
China-based Shanghai Henlius Biotech (HKG: 2696) has announced a strategic clinical study cooperation agreement with...